Eli Lilly 2008 Annual Report Download - page 78

PROXY STATEMENT
7676
Alfred G. Gilman, M.D., Ph.D. Age 67 Director since 1995
Executive Vice President for Academic Affairs and Provost, The University of Texas South-
western Medical Center at Dallas; Dean, Southwestern Medical School; and Regental
Professor of Pharmacology and Director of the Cecil and Ida Green Center for Molecular,
Computational, and Systems Biology, The University of Texas Southwestern Medical Center
Dr. Gilman has served as executive vice president for academic affairs and provost of the
University of Texas Southwestern Medical Center at Dallas and dean of the University of
Texas Southwestern Medical School since 2005 and professor of pharmacology at the Uni-
versity of Texas Southwestern Medical Center since 1981. He holds the Raymond and Ellen
Willie Distinguished Chair of Molecular Neuropharmacology, the Nadine and Tom Craddick
Distinguished Chair in Medical Science, and the Atticus James Gill, M.D., Chair in Medical
Science at the university and was named a regental professor in 1995. Dr. Gilman was on
the faculty of the University of Virginia School of Medicine from 1971 to 1981 and was named
a professor of pharmacology there in 1977. He is a director of Regeneron Pharmaceuticals,
Inc. Dr. Gilman was a recipient of the Nobel Prize in Physiology or Medicine in 1994.
Karen N. Horn, Ph.D. Age 65 Director since 1987
Retired President, Private Client Services, and Managing Director, Marsh, Inc.
Ms. Horn served as president of Private Client Services and managing director of Marsh,
Inc. from 1999 until her retirement in 2003. Prior to joining Marsh, she was senior managing
director and head of international private banking at Bankers Trust Company; chairman and
chief executive offi cer of Bank One, Cleveland, N.A.; president of the Federal Reserve Bank
of Cleveland; treasurer of Bell Telephone Company of Pennsylvania; and vice president of
First National Bank of Boston. Ms. Horn serves as director of T. Rowe Price Mutual Funds;
The U.S. Russia Investment Fund, a presidential appointment; Simon Property Group, Inc.;
and Norfolk Southern Corporation. Ms. Horn has been senior managing director of Brock
Capital Group since 2004.
John C. Lechleiter, Ph.D. Age 55 Director since 2005
Chairman, President, and Chief Executive Offi cer
Dr. Lechleiter became chairman of Eli Lilly and Company on January 1, 2009. Dr. Lechleiter
was named president and chief executive offi cer of the company in April 2008. He served as
president and chief operating offi cer from 2005 to 2008. He joined Lilly in 1979 as a senior
organic chemist and has held management positions in England and the U.S. He was named
vice president of pharmaceutical product development in 1993 and vice president of regula-
tory affairs in 1994. In 1996, he was named vice president for development and regulatory
affairs. Dr. Lechleiter became senior vice president of pharmaceutical products in 1998, and
executive vice president of pharmaceutical products and corporate development in 2001. He
was named executive vice president of pharmaceutical operations in 2004. He is a member
of the American Chemical Society. Dr. Lechleiter serves as a member of the executive com-
mittee of the board of directors of Pharmaceutical Research and Manufacturers of America
(PhRMA) and as a member of the Business Roundtable and the Business Council. He also
serves as a member of the Visiting Committee of Harvard Business School and a member
of the board of trustees of Xavier University (Cincinnati, Ohio). In addition, he serves as a
distinguished advisor to The Children’s Museum of Indianapolis and a member of the United
Way of Central Indiana board of directors.